Clinical Outcomes with Unfractionated Heparin Monitored by Anti-Factor Xa vs. Activated Partial Thromboplastin Time.
Am J Hematol. 2019 Jun 26;:
Authors: Coons JC, Iasella CJ, Thornberg M, Fitzmaurice MG, Goehring K, Jablonski L, Leader D, Meyer A, Seo H, Benedict NJ, Smith RE
Anti-factor Xa (anti-Xa) monitoring of unfractionated heparin (UFH) is associated with less time to achieve therapeutic anticoagulation compared to the activated partial thromboplastin time (aPTT). However, it is unknown whether clinical outcomes differ between these methods of monitoring. The aim of this research was to compare the rate of venous thrombosis and bleeding events in patients that received UFH monitored by anti-Xa compared to the aPTT. A retrospective review of electronic health records identified adult patients that received UFH given intravenously (IV) for ≥ 2 days with either anti-Xa or aPTT monitoring at an academic tertiary care hospital. This was a pre/post study design conducted between January 1-December 30, 2014 (aPTT) and January 1-December 30, 2016 (anti-Xa). All UFH adjustments were based on institutional nomograms. The primary outcome was venous thrombosis and the secondary outcome was bleeding, both of which occurred between UFH administration and discharge from the index hospitalization. A total of 2,500 patients were in the anti-Xa group and 2,847 patients aPTT group. Venous thrombosis occurred in 10.2% vs. 10.8% of patients in the anti-Xa and aPTT groups, respectively (p = 0.488). Bleeding occurred in 33.7% vs. 33.6% of patients in the anti-Xa and aPTT groups, respectively (p = 0.94). Anti-Xa monitoring was not an independent predictor of either outcome in multivariate logistic regression analyses. Our study found no difference in clinical outcomes between anti-Xa and aPTT-based monitoring of UFH IV. This article is protected by copyright. All rights reserved.
PMID: 31243789 [PubMed - as supplied by publisher]